Generic Medicine Info
Tab: Should be taken on an empty stomach (i.e. At least one hour before food or two hours after food).
Cap: May be taken with or without food. Take consistently either always w/ or always w/o meals.
History of bronchial asthma, bronchospasm chronic obstructive airways disease, bradycardia, cardiogenic shock, hypotension, metabolic acidosis, severe peripheral arterial circulatory disturbances, 2nd or 3rd degree heart block, sick sinus syndrome, untreated pheochromocytoma, uncontrolled heart failure, Prinzmetal's angina.
Special Precautions
Patient with Raynaud's disease or intermittent claudication, 1st degree heart block, diabetes mellitus, myasthenia gravis, psoriasis, thyroid disease. Avoid abrupt withdrawal. Hepatic and renal impairment. Elderly. Pregnancy and lactation. Patient Counselling This drug may cause dizziness, if affected, do not drive or operate machinery. Monitoring Parameters Monitor blood pressure, heart rate,ECG, and serum glucose (in patients with diabetes mellitus).
Adverse Reactions
Blood and lymphatic system disorders: Agranulocytosis, thrombocytopenia. Cardiac disorders: Bradycardia, cardiac failure, AV block. Eye disorders: Visual disturbances, dry eye, conjunctivitis. Gastrointestinal disorders: Nausea, vomiting, diarrhoea, constipation, dry mouth. General disorders and administration site conditions: Lethargy, fatigue. Immune system disorders: Hypersensitivity, anaphylactic reactions. Nervous system disorders: Dizziness. Psychiatric disorders: Hallucination, psychoses, depression, mood changes, confusion, memory loss, sleep disturbances, nightmares. Reproductive system and breast disorders: Impotence, erectile dysfunction. Respiratory, thoracic and mediastinal disorders: Bronchospasm. Skin and subcutaneous tissue disorders: Alopecia, psoriasiform reaction, skin rash. Vascular disorders: Hypotension, cold extremities, Raynaud's phenomenon.
Drug Interactions
May have potentiating effects on arterial conduction time and induce additive negative or inotropic effect with propafenone, amiodarone, quinidine, flecainide and Ca channel blockers. Concomitant administration with catecholamine-depleting drugs (e.g. reserpine), MAOIs or TCAs may cause additive effects and potentiate hypotension. Reduced antihypertensive effect with NSAIDs (e.g. ibuprofen, indometacin). May enhance vasoconstrictive action of ergot alkaloids. Coadministration with warfarin increases its bioavailability and prothrombin time. May enhance hypoglycaemic effects of insulin. Increased risk of hypotension and attenuation of the reflex tachycardia with anaesthetic drugs. Increased plasma concentration with lidocaine.
CIMS Class
Antimigraine Preparations / Beta-Blockers
ATC Classification
C07AA05 - propranolol ; Belongs to the class of non-selective beta-blocking agents. Used in the treatment of cardiovascular diseases.
Disclaimer: This information is independently developed by CIMS based on propranolol from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2022 CIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in